Godavari Biorefineries Ltd Receives Japanese Patent for Novel Cancer Treatment Compound
Godavari Biorefineries Ltd has been granted a patent in Japan for a compound intended for cancer treatment, demonstrating significant inhibitory effects against various aggressive cancers. The patent covers a novel class of compounds that show potent efficacy against cancer and cancer stem cells.The patented technology is noted to be particularly effective against multiple types of cancer, including breast and prostate cancer. This development highlights the company's work in advanced bio-refinery applications and therapeutic research.
The patent details cover the compound designated as "5-HYDROXY1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER." The registration confirmed the status of the invention according to the Japanese Patent Office records.
Key details regarding the intellectual property are as follows:
| Feature | Detail |
|---|---|
| Patent Title | 5-HYDROXY1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER |
| Patent Number | 7869786 |
| Patentee | Godavari Biorefineries Limited |
| Application Number | 特願２０２３－５２５５３３ |
| Registration Date | October 26, 2021 |
The invention was filed on May 26, 2026. The patent was granted by the Japanese Patent Office.
GODAVARIB Stock Price Movement
Shares of Godavari Biorefineries Limited are rallying as of 10:08 AM, trading up 6.29% or ₹17.90 to reach the current level of ₹302.30. The stock maintains significant momentum in live trading, with a robust volume of 198,504 shares exchanged so far.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.